Article Sidebar

PDF
Date Published: 05/07/2023
Abstract Views: 266
Views PDF: 112
DOI: https://doi.org/10.51298/vmj.v527i2.5891
Issue
Vol. 527 No. 2 (2023)
Section
Các bài báo
How to Cite
Nguyễn, Q. T., Nguyễn, K. T., Phạm, T. H., Nguyễn, V. N., & Bùi, V. T. (2023). EVALUATING OF RESULTS OF THE TREATMENT OF STAGE III NON-SMALL CELL LUNG CANCER WITH CHEMOTHERAPY PACLITAXEL CARBOPLATIN COMBINED WITH RADIATION THERAPY. Vietnam Medical Journal, 527(2). https://doi.org/10.51298/vmj.v527i2.5891

EVALUATING OF RESULTS OF THE TREATMENT OF STAGE III NON-SMALL CELL LUNG CANCER WITH CHEMOTHERAPY PACLITAXEL CARBOPLATIN COMBINED WITH RADIATION THERAPY

Quang Trung Nguyễn1, Khánh Toàn Nguyễn1, Thị Hường Phạm1,, Văn Nhật Nguyễn1, Văn Tuấn Bùi1
1 Nghe An Oncology Hospital

Main Article Content

Abstract

Aims: To evaluate response and side effects of patients with stage III Non-small-cell lung cancer who were treated first-line by Paclitaxel and Carboplatin combined with radiation therapy. Patients and method of study: Retrospective and prospective study on 35 non-small cell lung cancer patients in stage III treated by Paclitaxel and Carboplatin combined with radiation therapy from March 2019 to August 2022. Results: Median of age 66± 7,3, male/female: 6/1. 31/35 (88,6%) patients completed the full dose of chemotherapy and radiotherapy. Partial response was achieved in 23 patients (65,7%) and the rate of disease control is 85,7%. Anemia occurs in 14/35 patients (40%), mainly grade 1. The percentage of neutropenia is 28,6%, and there are no patients with grade 4 leukopenia, mostly grade 1, 2. Thrombocytopenia were observed in 1 (2,9%) patients, and no case of grade 3, 4. Non-hematologic toxicities were generally mild with grade 1, 2: esophagitis (37,2%), dermatitis (25,7%), pneumonia (20%). An increased level of elevated transaminases (11,4%), creatinine in blood (5.7%). Conclusion: Our finding shows that concurrent chemoradiotherapy with Paclitaxel Carboplatin regimen was safe and effective in grade III non-small cell lung cancer.

Article Details

Keywords

Paclitaxel Carboplatin, non-small cell lung cancer, stage III

References

1. Sung H, Ferlay J, Siegel R L (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 71 (3), 209-249.
2. Kelly K, Crowley J, Bunn P A, Jr., et al (2001). Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol, 19 (13), 3210-3218.
3. Vũ Hữu Khiêm (2017). Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ bằng phác đồ hóa - xạ trị v i kỹ thuật PET/CT mô phỏng, Đại học Y Hà Nội.
4. Belani C P, Choy H, Bonomi P, et al (2005). Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol, 23 (25), 5883-5891.
5. Yến L T (2019). Đánh giá kết quả hóa xạ trị đồng thời ung thư phổi không tế bào nhỏ giai đoạn IIIB, Luận án Tiến Sỹ y học, Đại học Y Hà Nội.
6. Takeshita J, Masago K, Fujita S, et al (2014). Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: A case series of 20 patients. Mol Clin Oncol, 2 (3), 454-460.
7. Le Chevalier T, Arriagada R, Quoix E, et al (1991). Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst, 83 (6), 417-423.
8. Rengan R, Rosenzweig K E, Venkatraman E, et al (2004). Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 60 (3), 741-747.
9. Bùi công Toàn T V T v c s (2014). Nghiên cứu đánh giá hiệu quả điều trị trong ung thư phổi không tế bào nhỏ bằng hóa - xạ trị đồng thời. Tạp chí y học thực hành,
10. Jiang Z Q, Yang K, Komaki R, et al (2012). Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys, 83 (1), 332-339.